Extended Data Table 2 Summary of most commonly reported adverse events

From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  1. AE denotes adverse event. Listed are the most frequently reported AEs (≥ 10% Overall) by decreasing frequency of preferred term.
Back to article page